# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

> **NCT06955988** · PHASE1 · RECRUITING · sponsor: **Allist Pharmaceuticals, Inc.** · enrollment: 120 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Non-small Cell Lung Cancer

## Interventions

- **DRUG:** AST2303 Tablets(ABK3376 Tablets) ，25mg
- **DRUG:** AST2303 Tablets(ABK3376 Tablets) ，50mg
- **DRUG:** AST2303 Tablets(ABK3376 Tablets) ，75mg
- **DRUG:** AST2303 Tablets(ABK3376 Tablets) ，100mg
- **DRUG:** AST2303 Tablets(ABK3376 Tablets) ，125mg

## Key facts

- **NCT ID:** NCT06955988
- **Lead sponsor:** Allist Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-04
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06955988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06955988, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06955988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*